Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Who Took Part

According to the abstract, 100 subjects were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

The presence and degree of non-alcoholic fatty liver disease (NAFLD) was assessed by the fatty liver index (FLI), and subjects were divided into three subgroups: (1) without NAFLD; (2) with borderline NAFLD; and (3) with NAFLD.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Some subjects received a placebo instead of Copper (Supplement), giving a reference point.

Anthropometric, cardiometabolic, and hepatic parameters were assessed at baseline and at the end of follow-up.

Carotid intima-media thickness and endothelial function were assessed by doppler ultrasound and by flow-mediated dilation of the brachial artery, respectively.

What Was Measured

The subject headings attached to it are Biomarkers, Cardiovascular Diseases, Chlorogenic Acid, Dietary Supplements, Liver, Luteolin and Metabolic Syndrome.

The authors tagged it with the keywords cynara, diabetes mellitus, non-alcoholic fatty liver disease and type 2.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 100 subjects.

The publication is from 2019 (Nutrients), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.